---
title: "Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AAN | American Academy of Neurology |
| AChR | Acetylcholine receptor |
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| BCMA | B-cell maturation antigen |
| BLA | Biologics license application |
| C5 | Complement component 5 |
| CAR | Chimeric antigen receptor |
| CAR-T | Chimeric antigen receptor T-cell (therapy) |
| CD | Cluster of differentiation |
| cGMP | Current good manufacturing practice |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CRS | Cytokine release syndrome |
| DNA | Deoxyribonucleic acid |
| DRG | Diagnosis-related group |
| EBMT | European Society for Blood and Marrow Transplantation |
| EQ-5D-5L | EuroQol 5-dimension, 5-level questionnaire |
| evLYG | Equal value of life-years gained |
| FcRn | Neonatal Fc receptor |
| FDA | U.S. Food and Drug Administration |
| FY | Fiscal year |
| G-CSF | Granulocyte colony-stimulating factor |
| gMG | Generalized myasthenia gravis |
| HIV | Human immunodeficiency virus |
| HSV | Herpes simplex virus |
| ICAHT | Immune effector cell-associated hematotoxicity |
| ICANS | Immune effector cell-associated neurotoxicity syndrome |
| ICER | Institute for Clinical and Economic Review |
| IgG | Immunoglobulin G |
| IRR | Infusion-related reaction |
| ITT | Intention-to-treat |
| IV | Intravenous |
| IVIg | Intravenous immunoglobulin |
| JACIE | Joint Accreditation Committee of ISCT and EBMT |
| JAK | Janus kinase |
| JDM | Juvenile dermatomyositis |
| LRP4 | Low-density lipoprotein receptor-related protein 4 |
| MG | Myasthenia gravis |
| MG-ADL | Myasthenia Gravis Activities of Daily Living |
| MG-QoL-15r | Myasthenia Gravis Quality of Life 15-item revised |
| MGC | Myasthenia Gravis Composite |
| MGFA | Myasthenia Gravis Foundation of America |
| MGTX | Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone |
| mITT | Modified intention-to-treat |
| mRNA | Messenger ribonucleic acid |
| MS-DRG | Medicare severity diagnosis-related group |
| mTOR | Mechanistic target of rapamycin |
| MuSK | Muscle-specific tyrosine kinase |
| NCI | National Cancer Institute |
| NHS | National Health Service |
| pDC | Plasmacytoid dendritic cell |
| PIS | Postintervention status |
| QALY | Quality-adjusted life-year |
| QMG | Quantitative Myasthenia Gravis |
| REMS | Risk Evaluation and Mitigation Strategy |
| RNA | Ribonucleic acid |
| SAE | Serious adverse event |
| SD | Standard deviation |
| UK | United Kingdom |
| US | United States |
| USD | U.S. dollars |

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
